Q-omics provides the consensus-scored RPL21P108 profile across patient tissues and cancer cell-line models. RPL21P108 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, RPL21P108 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, RPL21P108 RNA expression shows 9,650 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THYM, KICH, and LSCC as cancer lineages where RPL21P108 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P108 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P108 survival associations across molecular data types. RPL21P108 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P108 RNA expression–survival associations across cancer types. High RPL21P108 expression shows unfavorable associations in THYM, KICH and STAD, but favorable associations in KIRC, LGG and UCEC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for RPL21P108 RNA expression.
This table summarizes RPL21P108 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P108. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P108 shows lower tumor expression in KICH, KIRC and LUSC. The KICH box plot shows higher RPL21P108 RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p < 0.001).
This table shows molecular features associated with RPL21P108 in patient tissues and cancer cell lines. In patient samples, RPL21P108 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
